Safety and Immunogenicity of a Nipah Virus Vaccine

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
A first-in-human, phase 1 trial is to be conducted in a healthy adult population in the US to assess the safety and immunogenicity of three ascending Nipah vaccine (HeV-sG-V; Hendra virus soluble glycoprotein vaccine) dosages. Different dosing regimens and number of doses will also be explored.
Epistemonikos ID: aa81de1d36f0fe588a8e5934f7f8675deea5d2a2
First added on: Mar 23, 2020